Intramuscular Injectable Generic Ketamine for use in an FDA Approved Emergency Use... Tender

Procurement Summary

Country : USA

Summary : Intramuscular Injectable Generic Ketamine for use in an FDA Approved Emergency Use Authorization (EUA)

Deadline : 03 Jan 2025

Other Information

Notice Type : Tender

TOT Ref.No.: 111989726

Document Ref. No. : HT9425-25-RFI-Ketamine-EUA

Competition : ICB

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : Refer Document

Purchaser's Detail

Name :Login to see tender_details

Address : Login to see tender_details

Email : Login to see tender_details

Login to see details

Tender Details

Description

In accordance with Federal Acquisition Regulation (FAR) 15.201 "Exchange with industry before receipt of proposals, " this RFI is for information and planning purposes only at this time and shall not be construed as a solicitation or as an obligation on the part of the Unites States Army Medical Research and Development Command (USAMRDC), USAMRAA, USAMMDA or any collaborative Department of Defense (DoD) activities.

This RFI is for information and planning purposes only and is neither to be construed as a commitment by the Government nor will the Government pay for information solicited. Respondents are solely responsible for all expenses associated with responding to this RFI. No evaluation letters and/or results will be issued to the respondents. Currently, no solicitation exists; therefore, please do not request a copy of the solicitation. NO PHONE CALLS WILL BE ACCEPTED OR RETURNED

Neither unsolicited proposals nor any other kind of offers will be considered in response to this RFI. Responses to this notice are not offers and will not be accepted by the Government to form a binding contract. In keeping with the standards of FAR Part 10, the Government may request additional information from responders. Responders are solely responsible for all expenses associated with responding to this RFI or any follow-up information request. All information received in response to this RFI or any follow-up information request that is marked Proprietary will be handled accordingly. Responses to the RFI will not be returned. At this time, questions concerning the composition and requirements for a future request for proposal will not be entertained.

USAMMDA WPAC PMO is conducting market research to determine the feasibility of securing and partnering with a manufacturer(s) for the procurement of generic ketamine for intramuscular injection (IM). No other route of ketamine administration or combination product(s), including autoinjectors and pre-filled ...
Active Contract Opportunity
Notice ID : HT9425-25-RFI-Ketamine-EUA
Related Notice
Department/Ind. Agency : DEPT OF DEFENSE
Sub-tier : DEFENSE HEALTH AGENCY (DHA)
Office: ARMY MED RES ACQ ACTIVITY
General Information
Contract Opportunity Type: Sources Sought (Updated)
Updated Published Date: Dec 17, 2024 02:52 pm EST
Original Published Date: Nov 20, 2024 02:46 pm EST
Updated Response Date: Jan 03, 2025 04:00 pm EST
Original Response Date: Dec 20, 2024 04:00 pm EST
Inactive Policy: 15 days after response date
Updated Inactive Date: Jan 18, 2025
Original Inactive Date: Jan 04, 2025
Initiative: None

Classification
Original Set Aside:

Product Service Code:
NAICS Code:
Place of Performance: Frederick, MD 21702 USA

Documents

 Tender Notice

A.docx